% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Regnery:143134,
      author       = {S. Regnery$^*$ and S. Adeberg and C. Dreher$^*$ and J.
                      Oberhollenzer$^*$ and J.-E. Meissner$^*$ and S. Goerke$^*$
                      and J. Windschuh$^*$ and K. Deike-Hofmann$^*$ and S.
                      Bickelhaupt$^*$ and M. Zaiss and A. Radbruch$^*$ and M.
                      Bendszus and W. Wick$^*$ and A. Unterberg and S. Rieken and
                      J. Debus and P. Bachert$^*$ and M. Ladd$^*$ and H.-P.
                      Schlemmer$^*$ and D. Paech$^*$},
      title        = {{C}hemical exchange saturation transfer {MRI} serves as
                      predictor of early progression in glioblastoma patients.},
      journal      = {OncoTarget},
      volume       = {9},
      number       = {47},
      issn         = {1949-2553},
      address      = {[S.l.]},
      publisher    = {Impact Journals LLC},
      reportid     = {DKFZ-2019-00743},
      pages        = {28772-28783},
      year         = {2018},
      abstract     = {To prospectively investigate chemical exchange saturation
                      transfer (CEST) MRI in glioblastoma patients as predictor of
                      early tumor progression after first-line treatment.Twenty
                      previously untreated glioblastoma patients underwent CEST
                      MRI employing a 7T whole-body scanner. Nuclear Overhauser
                      effect (NOE) as well as amide proton transfer (APT) CEST
                      signals were isolated using Lorentzian difference (LD)
                      analysis and relaxation compensated by the apparent
                      exchange-dependent relaxation rate (AREX) evaluation.
                      Additionally, NOE-weighted asymmetric magnetic transfer
                      ratio (MTRasym) and downfield-NOE-suppressed APT (dns-APT)
                      were calculated. Patient response to consecutive treatment
                      was determined according to the RANO criteria. Mean signal
                      intensities of each contrast in the whole tumor area were
                      compared between early-progressive and stable
                      disease.Pre-treatment tumor signal intensity differed
                      significantly regarding responsiveness to first-line therapy
                      in NOE-LD (p = 0.0001), NOE-weighted MTRasym (p = 0.0186)
                      and dns-APT (p = 0.0328) contrasts. Hence, significant
                      prediction of early progression was possible employing
                      NOE-LD (AUC = 0.98, p = 0.0005), NOE-weighted MTRasym (AUC =
                      0.83, p = 0.0166) and dns-APT (AUC = 0.80, p = 0.0318). The
                      NOE-LD provided the highest sensitivity $(91\%)$ and
                      specificity $(100\%).CEST$ derived contrasts, particularly
                      NOE-weighted imaging and dns-APT, yielded significant
                      predictors of early progression after fist-line therapy in
                      glioblastoma. Therefore, CEST MRI might be considered as
                      non-invasive tool for customization of treatment in the
                      future.},
      cin          = {E010 / E020 / E012 / G370},
      ddc          = {610},
      cid          = {I:(DE-He78)E010-20160331 / I:(DE-He78)E020-20160331 /
                      I:(DE-He78)E012-20160331 / I:(DE-He78)G370-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29983895},
      pmc          = {pmc:PMC6033360},
      doi          = {10.18632/oncotarget.25594},
      url          = {https://inrepo02.dkfz.de/record/143134},
}